Hereditary/Familial Ovarian Cancer: Testing Principles and Risk Management

Presented by:
Leigha Senter
Search for other papers by Leigha Senter in
Current site
Google Scholar
PubMed
Close
 MS, CGC
Restricted access

Although BRCA1 and BRCA2 pathogenic or likely pathogenic variants are a well-established cause of hereditary ovarian cancer, recent studies have brought other homologous recombination repair pathway genes into the limelight. The current NCCN Guidelines reflect the most up-to-date, evidence-based data relating to the risk management of patients who are carriers of BRCA1/2 and/or other variants. Risk-reducing bilateral salpingo-oophorectomy is the current standard of care, but a recommendation for salpingectomy alone may be on the horizon.

Disclosures: Ms. Senter has disclosed receiving consulting fees from and serving on the product/speakers bureau for AstraZeneca Pharmaceuticals LP; and serving as a scientific advisor for GlaxoSmithKline.

Correspondence: Leigha Senter, MS, CGC, The Ohio State University Comprehensive Cancer Center, 2012 Kenny Road, Columbus, OH 43221. Email: Leigha.Senter@osumc.edu
  • Collapse
  • Expand
  • 1.

    Daly MB, Pal T, AlHilli Z, et al. NCCN Clinical Practice Guidelines in Oncology: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic. Version 3.2023. Accessed April 9, 2023. To view the most recent version, visit https://www.nccn.org

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 2.

    Lancaster JM, Powell CB, Chen LM, et al. Society of Gynecologic Oncology statement on risk assessment for inherited gynecologic cancer predispositions. Gynecol Oncol 2015;136:37.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 3.

    Konstantinopoulos PA, Norquist B, Lacchetti C, et al. Germline and somatic tumor testing in epithelial ovarian cancer: ASCO guideline. J Clin Oncol 2020;38:12221245.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 4.

    Senter L, O’Malley DM, Backes FJ, et al. Genetic consultation embedded in a gynecologic oncology clinic improves compliance with guideline-based care. Gynecol Oncol 2017;147:110114.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 5.

    Childers CP, Childers KK, Maggard-Gibbons M, et al. National estimates of genetic testing in women with a history of breast or ovarian cancer. J Clin Oncol 2017;35:38003806.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 6.

    Bednar EM, Oakley HD, Sun CC, et al. A universal genetic testing initiative for patients with high-grade, non-mucinous epithelial ovarian cancer and the implications for cancer treatment. Gynecol Oncol 2017;146:399404.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 7.

    Boyd J, Sonoda Y, Federici MG, et al. Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. JAMA 2000;283:22602265.

  • 8.

    Werness BA, Ramus SJ, DiCioccio RA, et al. Histopathology, FIGO stage, and BRCA mutation status of ovarian cancers from the Gilda Radner Familial Ovarian Cancer Registry. Int J Gynecol Pathol 2004;23:2934.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 9.

    Chen J, Bae E, Zhang L, et al. Penetrance of breast and ovarian cancer in women who carry a BRCA1/2 mutation and do not use risk-reducing salpingo-oophorectomy: an updated meta-analysis. JNCI Cancer Spectr 2020;4:pkaa029.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 10.

    Kuchenbaecker KB, Hopper JL, Barnes DR, et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA 2017;317:24022416.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 11.

    Finch APM, Lubinski J, Møller P, et al. Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation. J Clin Oncol 2014;32:15471553.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 12.

    Couch FJ, Shimelis H, Hu C, et al. Associations between cancer predisposition testing panel genes and breast cancer. JAMA Oncol 2017;3:11901196.

  • 13.

    Rebbeck TR, Kauff ND, Domchek SM. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst 2009;101:8087.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 14.

    Falconer H, Yin L, Grönberg H, et al. Ovarian cancer risk after salpingectomy: a nationwide population-based study. J Natl Cancer Inst 2015;107:dju410.

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 741 442 11
PDF Downloads 444 184 10
EPUB Downloads 0 0 0